In a move reflecting its change in attitude, the Food and Drug Administration (FDA) issued a new Final Guidance relating to its Breakthrough Devices Program in September. The guidance has now clarified that certain devices for life-threatening or irreversibly debilitating diseases or conditions may now qualify for the program. The Jimmy Buffett 1977 classic, “Changes in latitudes, changes in attitudes; Nothing remains quite the same” seems to aptly embody the shift in FDA’s stance.
The updated final guidance known as the “Breakthrough Devices Program” seeks to address regulatory processes and augment the development and expedited evaluation of such medical devices that offer more effective treatment or diagnosis for life-threatening or irreversibly debilitating ailments.
This recent shift is a part of FDA’s ongoing efforts to foster innovation in the realm of medical devices while ensuring stringent safety and efficacy standards. Legal professionals with clients in the healthcare sector, both providers, and manufacturers, should take note of these developments, which may present new possibilities for exploration and growth in this space.
You can read the full guidance on the official FDA website or refer to the official release published by Arnall Golden Gregory LLP for further details.